Alaunos Therapeutics, Inc.
TCRT
$1.48
-$0.02-1.33%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 300.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 300.00% | |||
| Cost of Revenue | -20.56% | 42.86% | |||
| Gross Profit | 18.75% | -40.80% | |||
| SG&A Expenses | 1.72% | -38.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.71% | -32.87% | |||
| Operating Income | 1.37% | 33.07% | |||
| Income Before Tax | 0.18% | 32.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.18% | 32.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.18% | 32.88% | |||
| EBIT | 1.37% | 33.07% | |||
| EBITDA | 1.29% | 33.05% | |||
| EPS Basic | 0.18% | 32.87% | |||
| Normalized Basic EPS | 0.18% | 32.87% | |||
| EPS Diluted | 0.18% | 32.87% | |||
| Normalized Diluted EPS | 0.18% | 32.87% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
